Anupam Rasayan Acquires 48.2% Stake in Bliss GVS Pharma for ₹299/share
Anupam Rasayan acquired a 48.2% stake in Bliss GVS Pharma for ₹299 per share. The transaction was funded by a ₹300 crore term loan and ₹1,450 crore from financial investors. The combined entity is expected to achieve over ₹4,000 crore in revenue and ₹834 crore in EBITDA.
This acquisition is a major strategic move for Anupam Rasayan, significantly expanding its business into a new segment of the pharmaceutical value chain and integrating it with its existing operations. The combined entity's projected revenue and EBITDA indicate a substantial increase in scale and market presence.
The acquisition of Bliss GVS Pharma represents a strategic expansion for Anupam Rasayan into finished dosage formulations, strengthening its pharmaceutical platform and creating significant potential for synergies and value creation. The funding structure also appears well-managed, preserving balance sheet capacity.
Anupam Rasayan India Limited (ARIL) has announced the successful completion of its acquisition of a 48.2% controlling stake in Bliss GVS Pharma Limited, with the consideration paid at ₹299 per share. This marks ARIL's third strategic inorganic transaction and its entry into finished dosage formulations. The acquisition, completed through wholly owned subsidiary Mates Visa Consultancy, follows a definitive agreement signed on May 23, 2026, and the subsequent mandatory open offer process.
The transaction was funded by a combination of a ₹300 crore term loan and approximately ₹1,450 crore raised through non-controlling, non-voting instruments from financial investors including Bain Capital, Trust Group, and Investec. This financing structure aims to support the acquisition while preserving balance-sheet capacity for future growth.
Bliss GVS Pharma, founded in 1984, is a branded formulations company with over 150 brands across various therapeutic segments. Its six manufacturing facilities in Maharashtra are certified by international quality and regulatory standards such as US FDA, EU-GMP, and WHO-GMP. Bliss GVS is also recognized as India's first EU-GMP certified suppositories manufacturer.
Mr. Anand Desai, Managing Director of Anupam Rasayan India Ltd., stated that the acquisition is a significant milestone in the company's long-term strategy to build a diversified, integrated, and innovation-led global pharmaceutical platform. He highlighted that this move strengthens ARIL's presence in finished pharmaceutical formulations, complementing its expertise in key starting materials, intermediates, and specialty chemicals.
The combined platform, including Anupam Rasayan, Tanfac Industries, Jayhawk Fine Chemicals, and Bliss GVS Pharma, is projected to have a pro-forma revenue exceeding ₹4,000 crore and an EBITDA of approximately ₹834 crore. The pro-forma revenue breakdown includes ₹1,676 crore from Anupam Rasayan standalone, ₹711 crore from Tanfac Industries, ₹722 crore from Jayhawk Fine Chemicals, and ₹927 crore from Bliss GVS Pharma.
The three strategic acquisitions – Tanfac Industries (backward integration), Jayhawk Fine Chemicals (global manufacturing and nearshoring), and Bliss GVS Pharma (forward integration into finished dosage formulations) – represent a progressive approach to inorganic growth. The Bliss GVS Pharma acquisition was made at approximately 24x LTM earnings, presenting an earnings-accretive opportunity.
What to do with a filing like this
Anupam Rasayan India Limited filed this with the NSE as a statutory disclosure, categorised under acquisition. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Anupam Rasayan India Limited. Read the original for the full detail.